Pradaxa Orders Issued in MDL 2385
Judge David Herndon, of the Southern District of Illinois, has issued three case management orders relating to In re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation, MDL number 2385.
The Initial Conference Order and Procedural Matters (CMO #1), Confidentiality Order (CMO #2), and Order Governing the Format of Production (CMO #3), were entered less than 10 days after the JPML transferred the MDL to Judge Herndon. The Panel transferred the cases to Judge Herndon because of his “willingness” and “ability” to handle this litigation. These orders, and the speed in which they were entered, highlight Judge Herndon’s committment to the “expeditious resolution of this litigation.” See MDL 2385 CMO #1.
Judge Herndon set the Initial Conference for 1:30 p.m. October 3, 2012, in Courtroom 7 in the United States Courthouse for the Southern District of Illinois. Prior to the Conference, Judge Herndon expects Counsel for the Parties to meet and discuss a number of issues including a timetable for dispositive motions, issues relating to the preservation of discoverable information, and issues relating to privileges, to name a few. Roger Denton, of Schlichter Bogard and Denton, has been coordinating with Counsel for Defendant Boehringer Ingelheim Pharmaceuticals, Inc. (“BIPI”) (the manufacturer of Pradaxa) since cases originally were filed in the Southern District of Illinois.
These orders, and all other CMOs filed in the MDL relate to all cases filed in the Southern District of Illinois and any “tag along actions” later filed in, removed to, or transferred to Judge Herndon’s court.